News Headlines

  1. Ono Received Manufacturing And Marketing Approval In Japan For XCOPRI Tablets For The Treatment Of Patients With Partial-Onset Seizures, With Or Without Secondary Generalized Seizures 9/16/2026

    Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced that Ono received manufacturing and marketing approval of XCOPRI (generic name: cenobamate) Tablets 12.5 mg, 50 mg, 100 mg, 200 mg (‟XCOPRI”) for the treatment of patients with partial-onset seizures, with or without secondary generalized seizures.

  2. Hovione Opens New Facility At New Jersey Campus, Doubling U.S. Spray Drying Capacity 9/16/2026

    Hovione, a globally-integrated pharmaceutical Contract Development and Manufacturing Organization (CDMO), has opened 89 Twin Rivers, a new 31,000-square-foot facility at its East Windsor, N.J. campus that doubles the company's U.S. spray drying capacity and further reinforces Hovione´s global leadership in this technology platform.

  3. 3PBIOVIAN Appoints Ponchi Kantt-Neaz As Global Executive Business Director, Marking A Milestone In Its oCommercial Strategy 9/16/2026

    3PBIOVIAN has appointed Ponchi Kantt-Neaz as Global Executive Business Director, marking an important milestone in the company’s global commercial strategy and further strengthening its commercial leadership as the company continues to expand its presence in the global CDMO market.

  4. Gilead Accelerates Global Access Planning For Investigational Once-Yearly Lenacapavir For HIV Prevention 9/16/2026

    Gilead Sciences, Inc. today announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP).

  5. Shilpa Biologicals And SPIMACO Bio Sign Strategic License Agreement For PD-1 Biosimilar For MENA Market 9/16/2026

    Shilpa Biologicals Private Limited, an integrated biologics development and manufacturing organisation, announces an exclusive Middle East and North Africa (MENA) strategic licensing and commercialization agreement with SPIMACO Bio of Saudi Arabia for portfolio of PD-1 inhibitor biosimilars across the Middle East and North Africa (MENA).

  6. Tempest Secures Exclusive Option To License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform 9/15/2026

    Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, today announced that it has entered into an exclusive option agreement with Hebei Senlang Biotechnology Co., Ltd. (“Senlang”).

  7. GSK To Acquire Potential Best-In-Class T Cell-Engager (TCE) For Multiple Myeloma From Chimagen Biosciences 9/15/2026

    GSK plc today announced it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) from Chimagen Biosciences (Chimagen), a privately held biotechnology company. GSK plans to develop and commercialise the asset for multiple myeloma, with the programme expected to enter phase I trials in 2027.

  8. VaxThera And Codagenix Partner To Advance A Next Generation Yellow Fever Vaccine 9/15/2026

    VaxThera S.A.S., a Colombian biotechnology company developing and manufacturing vaccines and advanced biological products ("VaxThera") and Codagenix Inc., a clinical-stage biotechnology company pioneering synthetic biology-based vaccines ("Codagenix"), today announced an agreement on terms for VaxThera to exclusively license Codagenix's yellow fever vaccine candidate, Syn17D-YF (CDX-470). Under the agreement, VaxThera plans to advance Syn17D-YF through manufacturing, preclinical and clinical development, regulatory registration, and commercialization in selected global markets.

  9. Ori Biotech Announces 10-Year, $120M Partnership To Advance Automated Manufacturing For Commercial Cell Therapies 9/15/2026

    Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, today announced a strategic collaboration with an undisclosed biopharmaceutical company to integrate the IRO platform into a commercial cell therapy manufacturing process in a deal valued at up to $120M in services, milestones, equipment and consumable purchases over the next 10 years.

  10. Samsung Biologics Signs USD 262 Million Manufacturing Agreement With European Pharmaceutical Company 9/15/2026

    Samsung Biologics’ new $262 million manufacturing agreement, extending through 2033, underscores strong long-term demand and business momentum as the company rapidly expands its global capacity, capabilities, and portfolio to support continued growth.